Head to head
Kisspeptin-10 against Kisspeptin-54
Two lengths of the same peptide with very different evidence. Kisspeptin-54 has genuinely good randomised data, all of it about triggering egg maturation in IVF, where it matured oocytes in 95 percent of 60 women at high risk of ovarian hyperstimulation syndrome with no moderate, severe or critical cases.
Column A
Kisspeptin-10Kisspeptin-10
A reproductive neuropeptide that triggers the body's own GnRH release, studied for fertility, hypogonadism, and sexual response.
Column B
Kisspeptin-54Kisspeptin-54, the 54 residue KISS1 gene product
Genuinely good randomised human evidence, all of it about triggering egg maturation in IVF: oocyte maturation in 95% of 60 women at high risk of ovarian hyperstimulation syndrome, with no moderate, severe or critical cases. Chronic dosing causes tachyphylaxis, a randomised trial found no effect on anxiety, and chronic subcutaneous dosing caused testicular degeneration in adult male rats.
Side by side, on the facts we can check
| Attribute | Kisspeptin-10 | Kisspeptin-54 |
|---|---|---|
| Category | Hormone | Hormone |
| FDA status | Investigational, not FDA-approved | Investigational. No approved kisspeptin product exists in any jurisdiction. The IVF trigger work is phase 2 and has not been taken to a registrational phase 3 programme. |
| Half-life | Short (minutes) | No human pharmacokinetic curve is asserted here because none was resolved in this pass. What the trials report instead is the downstream effect: a single subcutaneous dose produces a luteinising hormone surge the investigators describe as lasting roughly half a day, which is a pharmacodynamic duration and not a plasma half-life. |
| Molecular weight | ~1,302 Da | A 54 residue peptide, roughly 6 kDa. |
| Mechanism | Activates kisspeptin receptors on GnRH neurons, prompting the body's own release of GnRH and downstream reproductive hormones. | Demonstrated in humans, not proposed. Kisspeptin-54 binds KISS1R, formerly GPR54, on hypothalamic GnRH neurons, triggering release of an endogenous pool of GnRH, which drives pituitary luteinising hormone and follicle-stimulating hormone secretion. The downstream LH response has been measured directly in human trials by subcutaneous, intravenous and intranasal routes, and a single subcutaneous dose produces an LH surge the investigators describe as lasting roughly half a day. The receptor desensitises under continuous exposure, which is why chronic dosing produces tachyphylaxis rather than a sustained effect. |
| Human studies cited | 4 | 5 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Kisspeptin-10 and Kisspeptin-54?
Kisspeptin-10: A reproductive neuropeptide that triggers the body's own GnRH release, studied for fertility, hypogonadism, and sexual response. Kisspeptin-54: Genuinely good randomised human evidence, all of it about triggering egg maturation in IVF: oocyte maturation in 95% of 60 women at high risk of ovarian hyperstimulation syndrome, with no moderate, severe or critical cases. Chronic dosing causes tachyphylaxis, a randomised trial found no effect on anxiety, and chronic subcutaneous dosing caused testicular degeneration in adult male rats.
Which has stronger research evidence, Kisspeptin-10 or Kisspeptin-54?
This database does not grade compounds. It counts what was run in people: 4 of the 4 studies cited on the Kisspeptin-10 profile were human work, against 5 of 6 for Kisspeptin-54. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Kisspeptin-10 and Kisspeptin-54 FDA-approved?
Kisspeptin-10: Investigational, not FDA-approved. Kisspeptin-54: Investigational. No approved kisspeptin product exists in any jurisdiction. The IVF trigger work is phase 2 and has not been taken to a registrational phase 3 programme..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.